Digital measures offer enormous promise to bolster collective understanding of ADRD, including deepening our understanding of disease progression, defining new phenotypes, and supporting earlier diagnosis of disease. However, progress has been limited, with many of these efforts still in exploratory stages and very little work focused on understanding meaningful aspects of health in ADRD beyond cognitive features.

Further, digital measure development efforts have been disparate and siloed across therapeutic areas. The progressive nature of ADRD presents further challenges to novel digital measure development as patient, carepartner, and clinical unmet needs for meaningful measures change over time with disease progression.

The DiMe Measures that Matter publication advises that incorporating patient input is a dynamic process; it should be conducted continuously throughout the measurement selection process. To that end, individual patient and carepartner representatives are included in this project at each step as equal partners with pharma.

The DiMe Measures that Matter framework is guiding the development of a global mixed methods study across multiple regulatory regions, languages, and continents to identify measures that matter to Alzheimer's patients and their carepartners around the world.

✓ Measures that Matter is guiding research that will inform the development of a consensus set of core digital clinical measures in ADRD at the intersection of technological capabilities and global patient, carepartner, and clinical need.

✓ The global application of the framework will overcome the paucity of data and scientific knowledge about the causative factors and disease burden in non-white people.